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SUMMARY
Protein ubiquitination involves E1, E2, and E3 trienzyme cascades. E2 and RING E3 enzymes 
often collaborate to first prime a substrate with a single ubiquitin (UB) and then achieve different 
forms of polyubiquitination: multiubiquitination of several sites and elongation of linkage-specific 
UB chains. Here, cryo-EM and biochemistry show that the human E3 anaphase-promoting 
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complex/cyclosome (APC/C) and its two partner E2s, UBE2C (aka UBCH10) and UBE2S, adopt 
specialized catalytic architectures for these two distinct forms of polyubiquitination. The APC/C 
RING constrains UBE2C proximal to a substrate and simultaneously binds a substrate-linked UB 
to drive processive multiubiquitination. Alternatively, during UB chain elongation, the RING does 
not bind UBE2S but rather lures an evolving substrate-linked UB to UBE2S positioned through a 
cullin interaction to generate a Lys11-linked chain. Our findings define mechanisms of APC/C 
regulation, and establish principles by which specialized E3–E2–substrate-UB architectures 
control different forms of polyubiquitination.
Graphical abstract
INTRODUCTION
Posttranslational modification by multiple ubiquitins (UBs) or UB chains is a predominant 
eukaryotic mechanism regulating protein half-life, location, interactions, or other functions. 
After an E1 enzyme links UB to the catalytic Cys of an E2 enzyme (~30 in humans), the 
thioester-bonded E2~UB intermediate is employed by an E3 enzyme (~ 600 in humans) 
(Deshaies and Joazeiro, 2009). Most E3s display a domain that recruits a substrate's degron 
motif and a hallmark RING domain thought to bind a cognate E2~UB intermediate that 
determines acceptor Lys properties (Metzger et al., 2014; Streich and Lima, 2014). Some 
E2s promiscuously modify lysines irrespective of context, while others generate linkage-
specific UB chains (Christensen et al., 2007; Mattiroli and Sixma, 2014). Our current 
understanding is based on a limited number of landmark structures showing how RING 
domains align E2~UB active sites for nucleophilic attack, how a RING E3–E2 complex can 
target a preferred acceptor Lys, and how one RING forms homologous complexes with 
different E2~UB intermediates (Branigan et al., 2015; Dou et al., 2012; McGinty et al., 
2014; Plechanovová et al., 2012; Pruneda et al., 2012; Reverter and Lima, 2005; Scott et al., 
2014). However, structural models for dynamic polyubiquitination of substrates remain 
elusive.
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Visualizing substrate polyubiquitination is challenging because proteins are modified on 
assorted sites, and UB chains are often elongated in a linkage-specific manner where each 
distal UB progressively added to a growing chain is successively presented to the catalytic 
center to accept another UB. The multiple ubiquitination sites are essentially moving targets 
for a catalytic RING–E2~UB assembly. Furthermore, E3 RING and degron-binding domains 
are often flexibly tethered, raising the question of how catalytic encounter could be achieved 
(Berndsen and Wolberger, 2014; Streich and Lima, 2014). Here, we addressed how mobile 
RING E3–E2 assemblies and UB-linked substrates are positioned for modification of 
multiple substrate lysines and evolving UBs by the essential human E3, the 1.2 MDa 
multisubunit anaphase-promoting complex/cyclosome (APC/C) (King et al., 1995; Sudakin 
et al., 1995).
APC/C catalyzes polyubiquitination of key cell cycle regulators to control the metaphase-to-
anaphase transition, exit from mitosis, and maintenance of G1 (Primorac and Musacchio, 
2013; Wieser and Pines, 2015). A seemingly simplistic code for substrate binding, with 
degrons such as KEN- or D-boxes recruited via a coactivator (CDC20 or CDH1) and 
APC10, is complemented by assorted catalytic mechanisms to achieve the variety and timing 
of polyubiquitination required to distinctly regulate vastly diverse substrates. 
Polyubiquitination is catalyzed with two E2s (Rodrigo-Brenni and Morgan, 2007), in 
humans UBE2C and UBE2S, in multiple steps (Figure 1A) (Aristarkhov et al., 1996; 
Garnett et al., 2009; Williamson et al., 2009; Wu et al., 2010; Yu et al., 1996). The priming 
reaction, where a substrate receives a single UB from UBE2C, was explained by prior 
structures that revealed how KEN- and D-box substrates bind APC/CCDH1 and how APC/C's 
cullin–RING catalytic core recruits and positions UBE2C adjacent to the preferred target 
lysine in a substrate (Brown et al., 2015; Buschhorn et al., 2011; Chao et al., 2012; da 
Fonseca et al., 2011; Tian et al., 2012). Furthermore, an atomic structure showed APC/C is 
blocked by the inhibitor EMI1 (Chang et al., 2015). However, the structures did not explain 
APC/C-catalyzed polyubiquitination.
After the priming reaction, APC/C catalyzes two forms of substrate polyubiquitination: 
multiubiquitination and chain elongation. During multiubiquitination, UBE2C adds more 
UBs either individually or as short chains with various linkages, while UBE2S catalyzes 
Lys11-linked chain elongation from a substrate-linked UB (Williamson et al., 2009; Wu et 
al., 2010; Yu et al., 1996). Ultimately, different forms of polyubiquitination– i.e., multiple 
monoUBs, multiple Lys11-linked chains, and branched chains–direct APC/C substrate 
degradation with different efficiencies (Dimova et al., 2012; Grice et al., 2015; Lu et al., 
2015b; Meyer and Rape, 2014). Furthermore, processively polyubiquitinated substrates are 
degraded earlier in the cell cycle, whereas degradation occurs later for substrates receiving 
fewer UBs in a single encounter with APC/C. These latter substrates are subject to 
deubiquitination and competition with other substrates delaying their acquisition of a 
degradation signal (Kamenz et al., 2015; Lu et al., 2015a; Lu et al., 2014; Lu et al., 2015b; 
Rape et al., 2006). This is controlled in part by feed-forward processive affinity 
amplification (PAA), whereby relative to unmodified substrates, UB-linked substrates 
display higher affinity for APC/C, and are preferentially subjected to further rapid 
multiubiquitination by UBE2C followed by slower UB chain elongation by UBE2S (Lu et 
al., 2015c).
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How does a single E3 produce such polyubiquitination variety? Although UBE2C is 
activated by the canonical E2-binding site on APC11's RING domain (Brown et al., 2014), 
mechanisms underlying PAA remain unknown (Lu et al., 2015c). And while UBE2S 
requires a distinct UB-binding site on the RING, hereafter referred to as “exosite” for 
simplicity, UBE2S lacks a standard E2 RING-binding signature sequence and instead its 
residues required for activity do not correspond to known RING E3 functions (Figure 1B) 
(Brown et al., 2014; Kelly et al., 2014; Williamson et al., 2009; Wu et al., 2010). Structural 
mechanisms explaining APC/C's massive enhancement of UBE2S's efficiency for generating 
Lys11-linked di-UB linkages remain elusive (Brown et al., 2014; Kelly et al., 2014).
Here, we describe structural studies that relied on protein engineering and crosslinking to 
overcome transient interactions to visualize APC/C complexes with their E2s representing 
different forms of polyubiquitination. The data reveal how a malleable E3 synergizes with 
different E2s and evolving ubiquitinated substrates to adopt distinct catalytic architectures 
that define assorted products of polyubiquitination reactions.
RESULTS
Distinct RING Roles in Priming, Multiubiquitination, and UB Chain Elongation
Using our recombinant APC/CCDH1 system (Weissmann et al., 2016), we discovered 
mechanistic differences between priming, multiubiquitination, and UB chain elongation in 
reactions with two different RING mutants. The “RINGcE2” mutant impairs canonical 
E2~UB activation, while “RINGexo” bears Ala replacements for residues essential for 
recruiting the acceptor UB for chain elongation by UBE2S (Figure 1B) (Brown et al., 2014; 
Dou et al., 2012; Plechanovová et al., 2012; Pruneda et al., 2012). In reactions with either 
WT or methylated UB (meUB) that cannot form chains, we assayed modification of three 
variants of the canonical APC/C substrate cyclin B N terminus (CycBN) during a single 
encounter with the different versions of APC/C (Figure 1C). Consistent with canonical 
RING activation of UBE2C, priming (monitored with a single Lys version of *CycBN and 
meUB) and multiubiquitination (monitored with single Lys and WT versions of *CycBN and 
WT UB) were impaired by the RINGcE2 mutant. Also as expected, UBE2S-mediated UB 
chain elongation on a UB-fused CycBN* substrate that bypasses the need for priming was 
eliminated by the APC/C RINGexo mutant. Unexpectedly, however, this mutant also subdued 
formation of high molecular weight conjugates by UBE2C, thereby uncovering that 
multiubiquitination by UBE2C is mechanistically distinct.
Anchoring the RINGexo Site, UBE2C, and UBE2S for Structural Studies of 
Polyubiquitination
Structural studies of E3–E2–substrate complexes have depended on artificial reinforcement 
because the interactions are fleeting (Brown et al., 2015; McGinty et al., 2014; Reverter and 
Lima, 2005; Scott et al., 2014). To visualize APC/C–E2–substrate architectures underlying 
polyubiquitination we used protein engineering to strengthen interactions with the RING 
exosite, and then crosslinking to stabilize UBE2C and UBE2S positioned for 
multiubiquitination and UB chain elongation, respectively.
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First, a UB variant (UBv) with substantially increased affinity (1.6 μM KD) for APC11's 
RING was selected by phage display (Figure 2A) (Ernst et al., 2013). After determining the 
crystal structure of the APC11 RING–UBv complex, NMR and enzyme assays 
demonstrated that the corresponding surfaces mediate APC11 RING domain binding to UBv 
and to UB and vice-versa, titrating free UBv impedes multiubiquitination and UB chain 
elongation by WT APC/C in a manner paralleling the APC/C RINGexo mutant, and the UBv 
is specific for APC/C and does not affect activities of a related RING or an unrelated UB-
binding E3 (Figures 2A–2E, S1, Table S1). Furthermore, biological relevance was 
highlighted using a Xenopus egg extract system: the RINGexo-binding UBv, but not the 
negative control mutant, substantially slowed APC/C-dependent cyclin B degradation 
(Figure 2F). Although we cannot be certain that APC11-UBv and APC11-UB interactions 
are identical (a combination of mutations collaterally displace Lys11 so the UBv structure 
does not permit UBE2S-dependent chain elongation), the similarity between UBv and UB 
(0.37Å RMSD), and the numerous experiments indicating that to a first approximation UBv 
binds the same surface as a substrate-linked UB suggested that UBv would be a useful tool 
for anchoring the dynamic APC/CCDH1 RING exosite.
As a prelude to structural studies, we performed crosslinking based on the notion that 
connecting several weak interactors would enable avidly capturing multiple sites in 
ubiquitination complexes. The 3-headed sulfhydryl-reactive crosslinker TMEA 
simultaneously joined a C-terminal Cys on UB representing the donor, the active site Cys on 
either UBE2C or UBE2S, and optimized sites to represent multiubiquitination or UB chain 
elongation in surrogates for UB-linked substrates where UBv was fused to fragments 
derived from the substrate Hsl1 (Figures 2G, 2H, and S2). Avid binding of the respective 
substrate and/or E2 portions of the crosslinked products was confirmed by the 
multiubiquitination trap inhibiting overall UBE2C activity, substrate-binding, and UBE2C 
activation, and the UB chain elongation trap inhibiting UBE2S activation at substantially 
lower concentrations than individual components (Figure S2).
Cryo-EM Reconstructions of APC/C–E2 Complexes Poised for Polyubiquitination
Each trap was purified with APC/CCDH1, and cryo-EM was used to determine 3D 
reconstructions of the complex representing multiubiquitination with UBE2C at overall 
resolution of 6.4Å and that representing UB chain elongation with UBE2S to 6Å. The 
catalytic core, RING-UBv and E2 portions of maps displayed local resolutions of ~6–10 Å, 
apparently limited by conformational heterogeneity consistent with the dynamic 
mechanisms of polyubiquitination. Initial models constructed by docking atomic structures 
were improved by molecular dynamics flexible fitting (Figure S3, Movies S1 and S2). The 
donor UB is not visible even at low contour in either complex, consistent with local 
variability of the “closed” E2~UB conjugate in solution (Pruneda et al., 2012; Wickliffe et 
al., 2011). Overall, the EM data, together with structure-guided biochemical analyses, reveal 
molecular mechanisms of multiubiquitination and UB chain elongation.
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Structural “Snapshots” of APC/C–E2 Architectures Representing Steps in 
Polyubiquitination
To visualize steps in polyubiquitination, we compared the new EM reconstructions with 
prior data to provide “snapshots” along the process. EM maps were aligned representing 
substrate-bound APC/CCDH1 alone (Figure 3A) (Chang et al., 2014) and with UBE2C 
representing the priming reaction (Figure 3B) (Brown et al., 2015), alongside the maps 
representing multiubiquitination (Figure 3C) and UB chain elongation (Figure 3D). Side-by-
side comparisons show the remarkable ways the dynamic APC2–APC11 cullin-RING 
catalytic core, evolving ubiqui tinated substrates and E2s synergize to adopt distinct catalytic 
architectures specifying each reaction, illustrated beneath the EM reconstructions in Figure 
3.
Prior structural data showed how a substrate degron is anchored on one side of APC/C, with 
the D-box corecruited by CDH1 and APC10 (Figure 3A). However, without interacting 
partners APC/C's cullin-RING catalytic core is mobile and not well resolved (Chang et al., 
2014). How the mobile cullin-RING delivers the UBE2C~intermediate to substrate was 
revealed in a cryo-EM reconstruction representing “priming,” which showed UBE2C's 
active site juxtaposed with the preferred target site, stabilized by crosslinking (Figure 3B) 
(Brown et al., 2015). UBE2C~UB is positioned by both the APC11 RING and APC2 WHB 
domains, which emanate from the intermolecular APC2–APC11 cullin-RING interaction 
domain (C/R) (Figure 3B). UBE2C~UB is activated by binding the canonical E2 site on the 
RING, although primary recruitment occurs through APC2's WHB domain engaging the 
backside of UBE2C (Brown et al., 2015).
The cryo-EM reconstruction representing multiubiquitination provides insights into 
subsequent additional ubiquitination of a UB-linked substrate by APC/CCDH1–UBE2C 
(Figure 3C). UBE2C is placed in the same manner for multiubiquitination as for priming 
(Figure 3B, C). This positioning of UBE2C, through co-binding the APC11 RING and the 
APC2 WHB domains, condenses the search radius for multiple fluctuating lysines 
emanating from a tethered substrate. Reinspection of this geometry to understand 
multiubiquitination shows the active site of UBE2C located ~20 Å from the D-box. 
Importantly, this distance would allow numerous substrate lysines to access UBE2C and is 
large enough to accommodate a substrate-linked UB but small enough to constrain the 
catalytic geometry for generation of short chains (Figure 3C inset). UBv as a proxy for 
substrate-linked UB is bound to the RING exosite, providing a model for how this 
interaction would increase affinity and enhance processivity.
Finally, the new cryo-EM data reveal a completely different catalytic arrangement 
underlying APC/C-UBE2S-mediated UB chain elongation (Figure 3D). The “substrate” is 
recruited via a multisite mechanism, with the D-box binding CDH1 and APC10 on one side 
of APC/C, and the linked UBv localized by interactions with the RING exosite. This could 
place a homologous UB's K11 adjacent to UBE2S's active site. In agreement with prior 
mutational data (Brown et al., 2014; Kelly et al., 2014; Williamson et al., 2009), UBE2S is 
not recruited to the RING (Figure 3D). Furthermore, whereas RING domains typically bind 
the N-terminal portion of an E2 catalytic UBC domain, an APC2/APC4 groove binds 
UBE2S's unique C-terminal peptide (CTP), and APC2 interacts with the C-terminal portion 
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of UBE2S's UBC domain (Figure 3D). The density for the N-terminal portion of the UBE2S 
UBC domain disappears at higher resolution, presumably due to the combination of a lack of 
direct contacts and greater relative motion furthest from the APC/CCDH1-binding site 
(Figure S3B). Another difference from the priming and multiubiquitination catalytic 
architectures is that in the complex with UBE2S, APC2's WHB domain is not visible (Figure 
3D), consistent with dispensability for UB chain extension (Brown et al., 2015).
Different positions of the E2s in the complexes representing multiubiquitination and UB 
chain elongation would explain differences in products of these distinct polyubiquitination 
reactions. During multiubiquitination, UBE2C is placed in the central cavity, with its active 
site facing inside APC/C and proximal to substrate. This confines the space available for a 
modified substrate and would account for the limited number of UBs typically linked to 
substrates in reactions with UBE2C. By contrast, UBE2S is placed at the edge of APC/C 
(Figure 3D). This open architecture would allow growth of a polyUB chain either entirely 
outside APC/C altogether, or inside the central cavity (Figure 3D, inset). Further 
experiments examining how multiubiquitination is amplified by a substrate-linked UB 
binding the RING exosite and how UB chain elongation is determined are described in 
separate sections below.
RING Exosite Binding to Substrate-Linked UB Influences Processivity of 
Multiubiquitination
The structure representing multiubiquitination suggested that a substrate-linked UB binding 
to the RING exosite could provide a secondary interaction (Figure 3C). This may underlie 
findings from a recent single-molecule study, which showed that ubiquitinated substrates 
have a relatively higher propensity to bind APC/C, which drives their further 
multiubiquitination (Lu et al., 2015c). We used the single molecule assay to confirm the role 
for the RING exosite. Indeed, during multiubiquitination reactions with UBE2C where the 
UB linkages to substrate are evolving, the RING exosite mutant showed relatively decreased 
binding as probed by the number of APC/CCDH1 complexes detected in a field-of-view with 
saturating substrate (Securin) molecules, ~2 × 105, on the surface of a chip (Figure 4A).
This led to several predictions regarding mechanisms of multiubiquitination (Figures 4B and 
4C). Enhanced lifetime of a ubiquitinated substrate on APC/C would increase processivity, 
thereby increasing the extent of modification while concomitantly decreasing catalytic 
turnover of substrate. Thus, mutating the RING exosite would be predicted to both decrease 
the extent of modification, and to correspondingly increase the fraction of substrate modified 
during the reaction. The notable exception would be during a single substrate encounter with 
APC/CCDH1, if a particular substrate-linked UB could not access the RING, then blocking 
the exosite would not impact the extent of ubiquitination. CycBN* could be a suitable 
substrate for these experiments, because the EM data predict that only one of its 16 potential 
ubiquitination sites (Lys51) could not access UBE2C, and a short UB chain linked to all the 
sites could access the RING exosite. We confirmed the predictions for ubiquitination site 
usage using a proteolytic strategy that isolates most sites and subsequent semiquantitative 
mass spectrometry analysis of the resultant peptides (Figures S4A–S4C). Mutating the 
RING exosite only subtly perturbed the site usage.
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The predicted roles of the RING exosite on the extent of multiubiquitination were tested 
with several assays. First, we quantified UB chain formation using UB-AQUA, which 
showed a ~20 percent reduction in UB chains formed upon mutating the RING exosite 
without apparent discrimination toward a specific chain linkage (Figures 4D, S4B, and S3C). 
Second, we assayed various forms of multiubiquitination for a suite of CycBN* mutants with 
different numbers and locations of lysines. All acquired fewer UBs with the APC/CCDH1 
RINGexo mutant, except the one mutant predicted to have limited potential for PAA due to 
few target lysines: the RINGexo mutant does not substantially affect modification of the 
single Lys substrate in a single encounter with APC/C (Figures 1C, 4E, S4D–S4J).
The role of the RING exosite on the fraction of substrate turned over was monitored during 
multibiquitination time-courses. As predicted (Figure 4C), free substrate was more rapidly 
depleted in reactions with the RING exosite mutant (Figures 4E–4G, S4B, S4D–S4J). 
Quantifying the effects showed that a higher proportion of the CycBN* was modified by at 
least one UB in reactions with the RING exosite mutant (Figures 4F and 4G). However, a 
higher proportion of the ubiquitinated CycBN* substrate received four or more UBs from 
UBE2C with wild-type APC/CCDH1. The effects were magnified for the UB-fused CycBN* 
substrate, further implicating a role for substrate-linked UB binding to the RING exosite 
(Figures 4E–4G). Taken together, the results suggested that UB-binding to the APC11 RING 
exosite supports processive affinity amplification during multiubiquitination.
Unique UBE2S Tethering
UB chain extension is achieved by an entirely distinct mechanism. Our EM data reveal how 
APC/C uses a unique E3 architecture that (1) anchors UBE2S via a tether, (2) positions the 
active site, and (3) delivers the acceptor UB to UBE2S. Although the structural data agree 
with prior scanning mutagenesis data for the acceptor UB, UBE2S, and APC11's RING 
domain (Brown et al., 2014; Kelly et al., 2014; Wickliffe et al., 2011), we performed 
mutational studies of APC/C to both confirm the structure and define how the novel APC/C 
catalytic architecture establishes UB chain elongation.
We identified key APC/C residues recruiting UBE2S based on interactions with the basic/
hydrophobic tip of UBE2S's unique, flexible 66-residue C-terminal peptide (CTP) that is 
both necessary and sufficient for binding to APC/C (Williamson et al., 2009; Wu et al., 
2010). The EM reconstruction shows this nestled in a complementary acidic and 
hydrophobic groove at the interface between APC2's N-terminal domain (NTD), C/R 
domain, and APC4's β-propeller (Figures 5A and 5B). Although the homologous sequence 
from the inhibitor EMI1 was assigned to comparable density in a prior EM structure, 
individual side-chains have yet to be resolved for this region for either UBE2S or EMI1, and 
roles of the APC2/APC4 groove have not been tested (Chang et al., 2015). Our molecular 
model shows the APC2/APC4 groove including APC2's Asp350 and Asp353, and APC4's 
Asp33 and the loop spanning from Asp747 through Glu751, and their mutation specifically 
impairs APC/CCDH1-UBE2S-catalyed UB chain elongation without affecting 
multiubiquitination with UBE2C (Figure 5B, S5A–S5E). These APC2/APC4 groove 
mutations and the corresponding mutation from UBE2S's CTP (L222A) caused parallel 
defects, ~10- to 30-fold increases in apparent Km (Kmapp) with little effect on apparent Vmax 
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(Vmaxapp) in reactions monitoring polyubiquitination of a UB-fused substrate while titrating 
UBE2S (Figure 5C). Thus, the interaction between UBE2S's CTP and the APC2/APC4 
groove plays the predominant role in recruiting UBE2S, but other elements are crucial to 
activate UBE2S-mediated UB chain elongation.
Unique E2 and Acceptor Placement Promote Chain Elongation
UB chain elongation requires juxtaposition of an E2 active site with an acceptor UB. The 
EM density showed an unprecedented cullin-RING mechanism, whereby the cullin, not the 
RING, positions UBE2S. This provides a rationale for deleterious effects of mutating 
UBE2S's “C” and “D” helices (Brown et al., 2014; Kelly et al., 2014), which straddle a pair 
of APC2 C/R domain helices that we term SiA and SiB, for UBE2S-interacting A and B-
helices (Figure 5A and 5D, Movie S2). UBE2S binding to APC2's SiA and SiB-helices 
orients the active site toward the APC/C central cavity and APC11's tethered RING domain, 
and places the machinery catalyzing UB chain elongation at the extreme edge of APC/C's 
central cavity. This cullin function of APC2 may be specialized for APC/C, as the 
corresponding region in canonical cullins is not known to play a catalytic role.
Several assays validated that APC2 placement of UBE2S's UBC domain is important to 
activate UB chain elongation. Parallel effects are observed for mutations in the APC2 Si-
helices and the corresponding interacting C- and D-helices in UBE2S. Monitoring APC/
CCDH1-dependent chain elongation on a UB-primed substrate while titrating UBE2S showed 
that mutations disrupting the APC2–UBE2S UBC domain interface decreased Vmaxapp, 
without substantially impacting the Kmapp value for UBE2S (Figures 5E and S5F). In assays 
monitoring fluorescent UB transfer from UBE2S while titrating free UB as acceptor, the 
mutations caused increased Kmapp for the acceptor UB (3.5- to 7.5-fold) and decreased 
Vmaxapp (2- to 6-fold) (Figures 5F and S5G). Some mutations almost eliminated UB chain 
formation. Further support for APC2 placement of UBE2S's catalytic UBC domain comes 
from a compensatory charge-swap experiment, as defective UB chain elongation caused by 
the deleterious APC2 SiB-helix K562D mutation was specifically rescued by the structurally 
complementary E132R mutation from UBE2S's helix C (Figure 5G).
Subunit and domain deletion mutagenesis experiments confirmed that an APC2–APC11 
subcomplex containing the Si helices and RING domain is minimally required to activate di-
UB chain synthesis by UBE2S's isolated catalytic domain, albeit at 100-fold higher E3 
concentrations due to lack of CTP-recruitment (Figures 5H and S5H). In agreement with the 
structural data, robust CTP-dependent activation required preserving the APC2/APC4 
groove (Figure 5H). Importantly, even in the minimized systems, structure-based point 
mutations in APC2's Si helices thwarted activation of UBE2S-mediated di-UB synthesis 
(Figures S5I–S5K). NMR experiments further confirmed the distinctive interaction between 
APC/C's C/R and UBE2S's UBC domains: extreme line-broadening for resonances 
corresponding to 15N-UBE2S's folded UBC domain occurred upon adding an APC2–APC11 
subcomplex. This depended on intact Si helices but not the RING (Figures S6A–S6E).
To test if UB chain elongation involves APC/CCDH1 simultaneously engaging UBE2S's 
UBC and CTP domains as in the structure, we assayed a series of mutants with progressively 
shorter linkers connecting the domains. Indeed, only UBE2S variants with linkers that could 
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span the 30 Å distance separating the CTP and UBC domains retained full activity (Figure 
5I). Overall, the EM data suggest that it is essential to place UBE2S adjacent to the acceptor 
UB delivered by the RING exosite, as visualized by modeling UB in place of UBv in the 
EM reconstruction (Figure 5J).
UBE2S-Specific Assembly Elements Cannot Support UBE2C
Despite differences in catalytic architecture and the specific domains mediating interactions, 
there are some common principles underlying multiubiquitination and UB chain elongation 
(Figure 6A). First, APC/C recruits each E2 via auxiliary interactions: APC2's WHB binds 
UBE2C's backside while the APC2/APC4 groove recruits UBE2S's CTP. Second, the cullin-
RING catalytic core positions both E2s proximal to their distinctive acceptors, albeit by 
APC2's WHB and APC11's RING domains co-positioning UBE2C and by APC2's Si-
helices guiding UBE2S. To test if each E2 depends on its own interactions with APC/C, we 
wished to assay effects of transplanting their unique elements. Although we were unable to 
relocalize UBE2S to the site occupied by UBE2C, we were able to test if UBE2S-specific 
features could support APC/CCDH1 activity with UBE2C as follows.
First, we asked if UBE2S's CTP could substitute for APC2's WHB in recruiting UBE2C. We 
assayed a chimeric E2 harboring UBE2S's CTP grafted onto UBE2C (Chang et al., 2015). 
Control reactions showed that appending UBE2S's CTP does not hinder multiubiquitination 
with wild-type APC/CCDH1 (Figure 6B), and deleting the APC2 WHB domain does not 
impact UBE2S-catalyzed chain synthesis (Brown et al., 2015). However, >30-fold more of 
the UBE2C-UBE2SCTP chimera was required to multiubiquitinate CycBN* with the APC/
CCDH1 mutant lacking APC2's WHB domain (Figure 6B). Thus, UBE2C requires its 
distinctive APC/C binding mechanism.
Next, we asked if specific RING positioning is important using the elongation trap to 
shackle the RING away from the UBE2C-specific architecture (Figures 2H and 3D). The 
elongation trap blocked APC/CCDH1-dependent hydrolysis of an oxyester-linked 
UBE2C~UB complex, which requires RING-mediated activation independent of substrate 
(Figure 6C). Inhibition depended on redirecting the RING, because mutating the exosite to 
prevent UBv tethering of the RING restored activation in the presence of the elongation trap, 
and neither UBv nor substrate alone impaired activity.
Finally, we noted that the two catalytic architectures display different relative orientations 
for APC2's NTD and C/R domains. The helix at the hinge comprising residues 500–506 is 
largely buried in the EM reconstructions with UBE2C, but is partially exposed in complex 
with UBE2S. Accordingly, there is little effect of mutating hinge-helix isoleucines (501 and 
502) to aspartates on UBE2S-dependent polyubiquitination of a UB-fused substrate, whereas 
this substantially impairs multiubiquitination with UBE2C (Figure 6D). Thus, the distinctive 
cullin conformation is required for multiubiquitination.
Weak RING Interactions May Limit Competition between Multiubiquitination and Chain 
Elongation
Previous studies raised the question if multiubiquitination and UB chain elongation can 
occur simultaneously (Williamson et al., 2009; Wu et al., 2010). Indeed, priming, 
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multiubiquitination, and UB chain elongation can occur independently (Figure 1C), and both 
E2s can function during a substrate's single encounter with APC/CCDH1 (Wang and 
Kirschner, 2013), including on a substrate with a single Lys (Figure 6E). Nonetheless, there 
has been no evidence of synergy. Instead, single molecule kinetic experiments indicated that 
UBE2S can act after UBE2C in a second gradual phase of polyubiquitination (Lu et al., 
2015c).
To further explore the extent to which UBE2C and UBE2S could compete or catalyze their 
respective reactions simultaneously, we monitored activities of both E2s independently of 
each other but in the same tube using a donor meUB that cannot serve as acceptor, Cy5-
labeled C-terminally blocked UB that only accepts meUB from UBE2S, and fluorescein-
CycBN* or the single Lys version that only accept meUB from UBE2C. Increasing UBE2C 
to concentrations ~2-fold above Km slightly but reproducibly reduced di-UB synthesis by 
UBE2S (Figure 6F, 6G, S6F, and S6G), although no further inhibition was observed by 
adding more UBE2C. Such minor inhibition could be explained by competition between a 
UB-modified substrate and UBE2S acceptor UB for the RING exosite. Or RING positions 
for the two reactions could be mutually exclusive as observed in the EM reconstructions for 
the UBv-trapped structures (Figures 3C and 3D). Alternatively, it is also possible that WT 
UB binds the RING differently and could allow simultaneous engagement of UBE2C at the 
cE2 site and UBE2S's acceptor UB at the exosite. Irrespective of the mechanism, 
competition would be limited if RING interactions with different partners were fleeting. 
Indeed, UB-binding to the RING exosite is weak (Figure 2A) (Brown et al., 2014) and NMR 
chemical shift perturbation experiments did not detect interaction between 100 μM 15N-
labeled APC11 RING domain and 400 μM UBE2C or a disulfide-linked proxy for a 
UBE2C~UB intermediate (Figures S6H–S6J). Overall, it seems that the RING interactions 
visualized by trapping occur transiently in the context of multi-site binding during APC/
CCDH1-mediated polyubiquitination (Figure 3).
DISCUSSION
A major challenge in understanding RING E3 catalyzed polyubiquitination has been to 
explain how dynamically tethered substrates and mobile RING-E2 assemblies collide. We 
were able to address this through cryo-EM and biochemical analyses, which revealed 
distinct APC/C–E2–UB-linked substrate architectures specialized for distinct geometric 
challenges of multiubiquitination and UB chain elongation.
Multiubiquitination is specified by multisite interactions between APC/C's cullin-RING 
core, UBE2C, and a tethered UB-linked substrate that (1) secure UBE2C~UB to condense 
the search volume for catalytic encounter with the fluctuating substrate; (2) localize the 
active site proximal to substrate yet in a position that also accommodates a substrate-linked 
UB for further modification; and (3) additionally bind a primed substrate's linked UB to 
increase lifetime on APC/C and enhance processivity (Figure 7A). Constraining the 
proximity of substrate and UBE2C may contribute to preferential addition of individual UBs 
or short chains.
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Topological requirements for linkage-specific UB chain elongation are satisfied by 
specialized placement of UBE2S, which (1) employs an extraordinary cullin-RING 
mechanism–where the cullin binds E2 and RING binds the substrate-linked UB–to juxtapose 
UBE2S's active site and the acceptor UB and (2) localizes the catalytic center at the edge of 
APC/C, spatially allowing growth of long UB chains (Figure 7B). Because elements of the 
catalytic complex are flexible relative to each other, catalytic engagement of APC2–APC11, 
UBE2S, and the acceptor UB may occur dynamically, as in the various orientations observed 
for 3D classes in negative stain EM (Movie S2). Although future studies will be required to 
determine if and how UB binding to the RING and UBE2S binding to APC2 synergize for 
catalysis, a rationale for APC/C tracking substrate-linked UBs for chain elongation (Kelly et 
al., 2014) comes from the RING–UBv structure: interactions with a homologous acceptor 
UB would include the β1/β2-loop harboring Lys11, which after linkage to another UB 
would disengage from the catalytic assembly, thereby promoting further chain elongation.
Each architecture is optimal for its own form of polyubiquitination but suboptimal for the 
other activity. For example, the constrained assembly for multiubiquitination would hinder 
growth of long UB chains due to limited space between a substrate degron and E2 active site 
(Figure 7A). Meanwhile, the placement of UBE2S would be suboptimal for priming or 
multiubiquitination because the long distance between a tethered substrate's D-box and the 
active site would limit opportunities for catalytic encounter with substrate lysines (Figure 
7B).
It seems that the RING acting as a hub depends on individual interactions being weak, with 
multiple contacts converging to avidly support polyubiquitination architectures. While 
RING-UBE2C binding is undetectable in isolation, multisite interactions promote catalytic 
encounter (Figure 3C and S6H–S6J), after which the used UBE2C must dissociate from 
APC2–APC11 to be replaced by a charged UBE2C~UB for another UB to be ligated 
(Brown et al., 2015). On the opposite side of the RING, evolving substrate-linked UBs 
apparently transiently sample the exosite either to promote PAA during UBE2C-catalyzed 
multiubiquitination or for chain elongation by UBE2S without jamming the system. 
Although future studies and new tools will be required determine the precise structure of UB 
bound to APC11's RING during these reactions, UB binding may be “fuzzy” due to dynamic 
hydrophobic interactions, or may involve specific contacts dynamically presenting UB from 
various formats akin to UB chain binding to the proteasome. We speculate that APC/C, like 
the proteasome (Shi et al., 2016), has multiple weak UB binding site(s) awaiting discovery 
as either promotiong PAA, UB chain elongation, or regulation.
APC/C's diverse catalytic architectures could comprise a combinatorial system for 
decorating substrates with various UB conjugate topologies. Although the rules determining 
whether a ubiquitinated substrate is preferentially modified by UBE2C and/or UBE2S 
remain to be determined, we envision that numerous input signals, for example D- and 
KEN-box affinities for CDH1, relative substrate lysine positions, and propensity for further 
polyubiquitination by UBE2C or UBE2S establish a “mix-and-match” system for 
differentially modifying substrates to regulate their proteasomal degradation (Dimova et al., 
2012; Grice et al., 2015; Kirkpatrick et al., 2006; Lu et al., 2015b; Meyer and Rape, 2014).
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The different catalytic architectures are likely to be distinctly regulated. Some APC/C 
inhibitors, perhaps Mitotic Checkpoint Complex, could inhibit activity with UBE2C but still 
allow binding of UBE2S (Herzog et al., 2009; Kelly et al., 2014). Also, APC/C's assembly 
with the E2s is differentially regulated, for example by phosphorylation and protein 
interactions (Craney et al., 2016). Furthermore, UBE2C and UBE2S themselves undergo 
APC/C-dependent ubiquitin-mediated proteolysis through poorly characterized mechanisms 
(Garnett et al., 2009; Rape and Kirschner, 2004; Williamson et al., 2009; Wu et al., 2010). It 
is tempting to speculate that the two architectures enable the E2s to regulate each other. It 
seems likely that future studies will reveal how, when, and where the two catalytic 
architectures contribute to distinct APC/C functions and cell division.
Principles derived from the APC/C–E2 structures may apply to polyubiquitination by many 
RING E3s (Figure 7). Indeed, key features have parallels in other systems, including RING 
E3 collaboration with multiple E2s, multisite E3–E2 interactions, polyubiquitinating E2s 
forming an active conformation even without RING-binding, and UB-binding exosites in 
other E3s or E2s (Figure S7) (Metzger et al., 2014; Streich and Lima, 2014). APC/C 
presents fascinating re-use of a UB-binding exosite for different functions in distinct 
polyubiquitination architectures (Figure 7). The stage is now set for future studies aimed at 
understanding how other multidomain RING E3s dynamically respond in their own 
specialized ways to the distinctive features of multiple assorted E2~UB and ubiquitinated 
substrate partners to establish the enormous conjugate variety associated with cellular 
polyubiquitination.
EXPERIMENTAL PROCEDURES
Protein Purification
Proteins described are human, except sequences derived from Hsl1, the tight-binding APC/
CCDH1 substrate from S. cerevisiae. Baculoviruses expressing APC/C and subcomplexes 
were generated using biGBac (Weissmann et al., 2016). APC/C, subcomplexes, and UBA1 
were expressed insect cells, and all other proteins in bacteria, and purified as described 
(Brown et al., 2015; Brown et al., 2014). The multiubiquitination and elongation traps were 
generated in a manner similar to that described for the priming trap (Brown et al., 2015) but 
with modifications. For multiubiquitination, the “substrate” was a fusion between a KEN- 
and D-box containing fragment of Hsl1 and C-terminal UBv, with a single Cys in place of 
Hsl1 K788, and the E2 was a catalytic Cys only version of UBE2C (C102A) that is active in 
multiubiquitination. For elongation, the “substrate” was a fusion between UBv at the N 
terminus and a D-box containing fragment of Hsl1 with a single Cys in place of UBv K11, 
and the E2 was a catalytic Cys only version of UBE2S (C118F, linker 15, see Figures S2G–
S2L). 3-way crosslinking and trap purification were performed largely as described (Brown 
et al., 2015), except using the trifunctional sulfhydryl cross-linker TMEA (Pierce). For 
generation of samples for cryo-EM, APC/CCDH1 was first affinity purified based on tags on 
APC/C, the traps were added, and complexes were enriched by anti-Flag purification based 
on tags on the traps.
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Structural Studies
NMR, X-ray crystallography, and cryo-EM were performed largely as described previously 
(Brown et al., 2015).
Assays
Ubiquitination assays were performed largely as described (Brown et al., 2014), with some 
differences. APC/C, CDH1, substrate, E1, and E2 were mixed on ice prior to initiating 
reactions, which were performed at room temperature in buffer used for purification (20 mM 
HEPES pH 8.0, 200 mM NaCl, 1 mM DTT) supplemented with 5 mM MgCl2, 5 mM ATP, 
and 0.25 mg/mL BSA. For kinetic analyses, product bands were quantitated based on a 
fluorescein label on *UB, UB-CycBN*, or UB-Securin* (* denotes location of fluorescein, 
N- or C terminus) using a Typhoon FLA 9500 PhosphorImager. For APC/C-dependent 
substrate ubiquitination reactions, APC/C-independent products were subtracted as 
background. Details of assays in each figure are in Supplemental Experimental Procedures.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Cryo-EM shows mechanisms of polyubiquitination by cell-cycle 
regulator APC/C
• Distinct cullin-RING-E2 architectures for multiubiquitination and 
chain elongation
• RING activates UBE2C and binds substrate-linked ubiquitin to amplify 
processivity
• RING delivers ubiquitin for K11-linked chain elongation by UBE2S 
placed by cullin
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Figure 1. APC/C and Two E2 Partners Use Distinct Mechanisms for Polyubiquitination
(A) Distinct mechanisms of priming, multiubiquitination and UB chain elongation by 
APC/C, UBE2C, and UBE2S.
(B) Distinct APC11 RING surfaces involved in polyubiquitination: canonical E2 binding site 
- cE2; UB-binding exosite - Exo.
(C) APC11 RING mutants define distinctive priming, multiubiquitination, and UB chain 
elongation by APC/CCDH1 with UBE2C and/or UBE2S, using WT or methyl UB (meUB), 
during a single encounter of the indicated version of CycBN (1K = K67 only; UB- = UB-
fusion).
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Figure 2. Anchoring the RINGexo Site, UBE2C, and UBE2S for Structural Studies of 
Polyubiquitination
(A) Phage display selected UB variant (UBv) binds APC11 RING with high affinity and 
selectivity, measured by BLI.
(B) Crystal structure UBv (orange)–APC11 (navy) confirms binding to exosite, opposite 
canonical E2 site (modeled, cyan).
(C) UB and UBv bind similar APC11 RING surface and vice-versa, based on NMR 
chemical shift perturbations (CSPs).
(D) Similar effects on UBE2C-dependent multiubiquitination for blocking RING exosite 
with either UBv or APC11 mutations. Sponge = excess APC11 RING sequestering UBv.
(E) Similar effects on UBE2S-dependent UB chain elongation for blocking RING exosite 
with either UBv or APC11 mutations.
(F) UBv inhibits APC/C-dependent degradation of cyclin B in mitotic X. laevis egg extracts, 
examined by indicated westerns.
(G) Scheme of 3-way crosslinked complex used to trap APC/CCDH1–UBE2C architecture 
representing multiubiquitination.
(H) Scheme of 3-way crosslinked complex used to trap APC/CCDH1–UBE2S architecture 
representing UB chain elongation.
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Figure 3. “Snapshots” of Distinct APC/C–E2 Architectures for Polyubiquitination
(A) Prior APC/CCDH1–substrate complex (Chang et al., 2014). CDH1-purple, APC10-pink, 
APC2 NTD-light green, substrate-red.
(B) Prior structural data for complex representing priming (Brown et al., 2015), with 
UBE2C in light blue, APC2–APC11 intermolecular cullin–RING (C/R) domain green, and 
APC2 WHB domain in forest.
(C) Cryo-EM reconstruction representing multiubiquitination. UBv - orange. Inset, one UB 
(1UBQ, yellow) is shown fitting between substrate and active site.
(D) Cryo-EM reconstruction representing UB chain elongation. UBE2S - teal. Inset, 
distance between substrate binding and active sites accommodates polyUB, shown by 
tetraUB (2XEW, cartoon).
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Figure 4. Substrate-Linked UB Binding to RING Exosite Contributes to Processive Affinity 
Amplification for Multiubiquitination
(A) Single-molecule time traces for binding to evolving ubiquitinated immobilized Securin 
molecules during multiubiquitination by UBE2C and APC/CCDH1 or indicated RING 
mutants.
(B) In processive multiubiquitination by APC/C and UBE2C, multiple UBs are added to 
substrate in a single binding event.
(C) Model if blocking substrate-linked UB binding to the RING exosite reduces processivity 
and shifts to distributive mode of multiubiquitination. A larger fraction of substrate would be 
modified, but with fewer UBs.
(D) RING exosite contributes to quantity of UB chains formed during CycBN* 
multiubiquitination by APC/CCDH1 and UBE2C, measured by AQUA mass spectrometry.
(E) Role of UB-binding RING exosite on processivity, monitored by formation of high 
molecular weight conjugates and fraction of substrate modified during multiple turnover 
UBE2C-catalyzed multiubiquitination of CycBN* (top) or UB-CycBN* (bottom).
(F) Role of RING exosite on fraction of substrate modified over time, in assays as in (E), 
quantifying depletion of unmodified CycBN* (top) or UB-CycBN* (bottom). Error bars: 
SEM, N = 3.
(G) Role of RING exosite on extent of substrate modification during multiubiquitination 
with UBE2C. Ubiquitinated products generated as in (E) were divided into 2 categories, 
with ≥ 4 UBs (navy) or 1–3 UBs (blue) as resolved by SDS-PAGE to examine extent of 
generation of highly multiubiquitinated products. Error bars: SD, N = 3.
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Figure 5. Distinctive Multisite Interactions Establish Unique Catalytic Architecture Specifying 
UB Chain Elongation by APC/C and UBE2S
(A) Cryo-EM reconstruction of APC/C-CDH1 complex with UBE2S representing UB chain 
elongation as in Figure 3D, indicating regions with close-ups in panels (B), (D), and (J).
(B) Model for APC2/APC4 groove interactions with UBE2S CTP, based on docking APC/C 
structure (Chang et al., 2015) in cryo-EM reconstruction. APC2/APC4 groove is shown as a 
surface colored by electrostatic potential, with selected side-chains lining the groove in 
spheres. EM density for UBE2S CTP - cyan.
(C) Role of APC2/APC4 groove in recruiting UBE2S CTP, as determined from kinetic 
parameters for the indicated mutants during polyubiquitination of a UBSecurin substrate 
while titrating UBE2S. SEM, n ≥ 3.
(D) Placement of UBE2S C- and D-helices (cyan) by APC2 Si helices modeled based on 
(Chang et al., 2015) (green).
(E) Role of APC2 placement of UBE2S UBC domain in substrate polyubiquitination, from 
kinetic parameters for mutants during polyubiquitination of a UB-Securin substrate while 
titrating UBE2S. SEM, n ≥ 3.
(F) Role of APC2 placement of UBE2S UBC domain in activating UB chain synthesis, from 
kinetic parameters for mutants upon titrating acceptor UB during APC/CCDH1-UBE2S-
mediated di-UB synthesis. SEM, n ≥ 3.
(G) APC2 placement of UBE2S UBC domain tested by charge-swap rescue assaying 
UBE2S E132R restoring UB chain elongation specifically to APC/CCDH1 with APC2 
K562D mutant.
(H) Importance of placing UBE2S's UBC domain, or recruiting the CTP, determined from 
minimal APC/C subcomplexes (schematics on top) required to stimulate di-UB synthesis by 
WT UBE2S or isolated UBC domain lacking the CTP (bottom). Reactions with APC/C WT 
and subcomplexes 1–3 with WT UBE2S are controls based on (Brown et al., 2014).
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(I) Importance of placing both UBE2S's UBC domain and CTP for APC/C activation of UB 
chain elongation. UBE2S deletion mutants with progressively shorter linkers between the 
two domains were assayed for APC/CCDH1-dependent polyubiquitination of UB-CycBN*. 
Reactions with WT UBE2S and linker deletions to 26 are controls based on (Brown et al., 
2014).
(J) Model for acceptor UB (orange, UBv as proxy) in active site of UBE2S (cyan).
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Figure 6. Functional Specialization of Each Polyubiquitination Architecture
(A) Distinct APC/C mechanisms recruiting, positioning, and/or activating UBE2C or 
UBE2S for multiubiquitination and UB chain elongation, respectively.
(B) UBE2S CTP is a poor substitute for APC2 WHB in supporting UBE2C-dependent 
substrate multiubiquitination, as shown from assays with WT UBE2C or a chimera with 
appended UBE2S's CTP, and WT APC/CCDH1 or a deletion mutant lacking APC2 WHB 
domain.
(C) Shackling the RING away from the multiubiquitination architecture by the elongation 
trap inhibits APC/C activation of intrinsic UBE2C activity, monitored by inhibition of 
APC/CCDH1-stimulated hydrolysis of oxyester-linked UBE2C~UB.
(D) Specific APC2 cullin conformation is required for multiubiquitination. Top – schematic 
of distinctive APC2 NTD-C/R domain orientations showing burial or exposure of hinge. 
Distinct defects with hinge mutant (APC2 I501D, I502D) for multiubiquitination or UB 
chain elongation of UB-CycBN*.
(E) UBE2C and UBE2S build a UB chain on *CycBN-(1K) during the substrate's single 
encounter with APC/CCDH1.
(F) Competition between APC/CCDH1 activities with UBE2C and UBE2S probed 
simultaneously with 2 colors. MeUB can only be donor and not acceptor. Only fluorescein-
CycBN* (green) accepts meUB from UBE2C. Only Cy5-UB* (red) with blocked C terminus 
accepts meUB from UBE2S.
(G) Bar graphs showing reduced APC/CCDH1-UBE2S-catalyzed meUB~UB* formation in 
(F) and S6G in the presence of UBE2C activity. SD, n ≥ 2.
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Figure 7. Specialized APC/C–E2 Architectures for Multiubiquitination and UB Chain 
Elongation
(A) Processive multiubiquitination occurs by APC/C's APC2 cullin (green)-APC11 RING 
(blue) positioning UBE2C proximal to substrate (red), reducing the search volume for 
catalytic encounter while substrate-linked UB (yellow) binds the RING exosite to increase 
the evolving ubiquitinated substrate's lifetime on APC/C and enhance processivity. Each UB 
transfer cycle is accompanied by catalytic core dynamics releasing the used UBE2C for 
replacement by a charged UBE2C~UB to donate the next UB for ligation.
(B) Specialized architecture for UB chain elongation. APC2/APC4 recruits UBE2S's CTP, 
APC2 (cullin) places UBE2S's catalytic UBC domain, and APC11's RING guides the 
acceptor UB's Lys11 to the active site. Location of UBE2S at the edge of APC/C would 
accommodate growth of long UB chains.
Brown et al. Page 26
Cell. Author manuscript; available in PMC 2016 August 19.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
